OncoMatch/Clinical Trials/NCT07399821
An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma
Is NCT07399821 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies anti-GD2-800CW for neuroblastoma.
Treatment: anti-GD2-800CW — This is a non-randomized, open label phase Ib/II dose-escalation and expansion study designed to define the recommended dose of anti-GD2-800CW in pediatric neuroblastoma patients. The aim of this imaging study is to determine a safe and effective dose of anti-GD2-800CW for intra-operative detection of neuroblastoma using NIR fluorescence.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Neuroblastoma
Demographics
Prior therapy
Cannot have received: anti-GD2 antibody (Dinutuximab-beta)
Previous treatment with Dinutuximab-beta, either alone or in combination with chemotherapy
Cannot have received: chimeric antibody
Patients that received prior treatment with chimeric antibodies
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07399821 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-GD2 antibody, chimeric antibody disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 18 years or younger and at least 1 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages